Part 16, after stem cell treatment, 3 months already! 2march2013 Please note I made an error saying the date, it was the 2 March 2013 My name is Carole St-Laurent, I am from Rimouski, Quebec, Canada. I have a Spinal Muscular Atrophy from birth, it's in the family of Muscular Dystrophy. I received a stem cell treatment on the 28th of November 2012 at the "Integra Medical Center" in Nuevo Progresso Mexico, by Dr. Omar Gonzalez. This is a follow-up video. By: Kina Diamond … Continue reading →

Part 17, after stem cell treatment, exercises feeling better today, 3march2013 My name is Carole St-Laurent, I am from Rimouski, Quebec, Canada. I have a Spinal Muscular Atrophy from birth, it's in the family of Muscular Dystrophy. I received a stem cell treatment on the 28th of November 2012 at the "Integra Medical Center" in Nuevo Progresso Mexico, by Dr. Omar Gonzalez. This is a follow-up video. By: Kina Diamond … Continue reading →

Indications for Stem Cell Prolotherapy Caring Medical's Medical Director, Ross A. Hauser, MD, explains general indications for Stem Cell Prolotherapy, as done here in our office. If you have a severe chronic pain condition, sports injury, or osteoarthritis, we would be happy to talk to you in more detail about your case. Please email us through our website: http://www.caringmedical.com As always, thank you for watching! By: caringmedical … Continue reading →

NEW YORK, NY and PETACH TIKVAH, ISRAEL--(Marketwire - Mar 8, 2013) - BrainStorm Cell Therapeutics ( OTCQB : BCLI ), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today a poster presentation of clinical and scientific data at the 11th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2013) this week in Florence, Italy (http://www2.kenes.com/adpd/Pages/Home.aspx). "We are excited to be presenting our NurOwn technology at this important meeting," said Alon Natanson, Chief Executive Officer of BrainStorm Cell Therapeutics. "The AD/PD Conference brings international medical professionals together for a dynamic scientific program revealing cutting-edge research and discoveries diagnosing, preventing, and treating neurodegenerative diseases.We believe that our groundbreaking data on NurOwn will be well received by the attendees." In the coming months BrainStorm will be making a number of presentations at various international medical and research conferences as the scientific communities in Europe and the US are closely following the company's progress with its clinical development program. About NurOwnNurOwn is an autologous, adult stem cell therapy technology that differentiates bone marrow-derived mesenchymal stem cells (MSC) into specialized, neuron-supporting cells.These neuron-supporting cells (known as "MSC-NTF" cells) secrete neurotrophic, or nerve-growth, factors for PROTECTION of existing motor neurons, PROMOTION of … Continue reading →

NEW YORK, March 7, 2013 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue: The Market for Stem Cell Research Products: Current and Future Opportunities http://www.reportlinker.com/p01117629/The-Market-for-Stem-Cell-Research-Products-Current-and-Future-Opportunities.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy The market for stem cell research products continues to flourish. As stem cell research begins to yield actionable therapies, companies are investing resources in this area of research that stands to revolutionize the way many diseases are treated. Pharmaceutical and biotech companies are seeking to leverage portfolios beleaguered by high drug attrition rates and expiring patents, and the use of stem cells in the drug discovery phase, rapid developments in regenerative medicine and the emergence of novel cell- based therapies promise to offer exciting new revenue streams. Increasingly, industry and academic institutions are collaborating on stem cell research and product development. But given that practical stem-cell based therapies can take years to develop and are often stalled by heavy regulation, suppliers are in need of gaining a clear understanding of the wide range of products that support the stem cell research that is currently underway in both academic and industrial labs. The Market for Stem Cell Research Products: Current and Future Opportunities, BioInformatics LLC's latest report, was designed to … Continue reading →

Public release date: 7-Mar-2013 [ | E-mail | Share ] Contact: Sandy Van sandy@prpacific.com 808-526-1708 Cedars-Sinai Medical Center LOS ANGELES (March 11, 2013) Nobel laureate Roger Tsien, PhD, will keynote Cedars-Sinai's March 15 and 16 Nanomedicine for Imaging and Treatment Conference, which will assemble a multidisciplinary group of nationally and internationally renowned academic researchers, clinicians and representatives from private industry and the National Institutes of Health. Tsien, professor of pharmacology, chemistry and biochemistry at the University of California, San Diego, shared the 2008 Nobel Prize in chemistry for the discovery and development of the green fluorescent protein (GFP), which glows bright green and is found in one species of jellyfish. Among its biochemical uses, synthetic green fluorescent protein can be bound to other proteins to track their movement and behavior. Experts from two dozen organizations will lead sessions on identified and emerging issues in nanomedicine, focusing on recent achievements in drug delivery, nanomedicine and imaging, the role of the NIH in nanodrug development, and the latest preclinical and clinical advances in the treatment of cancer, neurodegenerative diseases and other conditions. The program was designed to provide many opportunities for those attending to talk and share ideas with members of the … Continue reading →

Newswise LOS ANGELES (March 11, 2013) Nobel laureate Roger Tsien, PhD, will keynote Cedars-Sinais March 15 and 16 Nanomedicine for Imaging and Treatment Conference, which will assemble a multidisciplinary group of nationally and internationally renowned academic researchers, clinicians and representatives from private industry and the National Institutes of Health. Tsien, professor of pharmacology, chemistry and biochemistry at the University of California, San Diego, shared the 2008 Nobel Prize in chemistry for the discovery and development of the green fluorescent protein (GFP), which glows bright green and is found in one species of jellyfish. Among its biochemical uses, synthetic green fluorescent protein can be bound to other proteins to track their movement and behavior. Experts from two dozen organizations will lead sessions on identified and emerging issues in nanomedicine, focusing on recent achievements in drug delivery, nanomedicine and imaging, the role of the NIH in nanodrug development, and the latest preclinical and clinical advances in the treatment of cancer, neurodegenerative diseases and other conditions. The program was designed to provide many opportunities for those attending to talk and share ideas with members of the faculty. Scientists specializing in nanotechnology and nanomedicine generally work with substances smaller than 100 nanometers. One nanometer … Continue reading →